Core Insights - Metsera, Inc. is presenting its portfolio of ultra-long acting therapies for obesity and metabolic diseases at the 85th Scientific Sessions of the American Diabetes Association (ADA) [1][2] - The lead program, MET-097i, is a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, with clinical data from its Phase 1/2 trial being showcased [2][4] - Additional presentations will cover preclinical data for MET-233i, an ultra-long acting amylin analog, and other differentiated portfolio assets [1][3] Presentation Highlights - MET-097i is highlighted as a potent and ultra-long-acting GLP-1 receptor agonist, with clinical data focusing on body weight change and tolerability after twelve weekly doses and a single monthly dose [2][4] - MET-233i will present preclinical data, including pharmacokinetic details and body weight change data [3][7] Presentation Details - Clinical presentations for MET-097i will occur on June 22, featuring two key sessions led by Metsera's executives [4][5][6] - Preclinical data for MET-233i will also be presented on the same date, showcasing its potential as an ultra-long-acting amylin receptor agonist [7] Pipeline Programs - Metsera is exploring therapeutic combinations, including ultra-long-acting GLP-1, GIP, glucagon, and amylin peptide analogs, which have shown promising results in inducing weight loss in preclinical models [8] - Health economics research will also be presented, highlighting the suboptimal titration to maintenance doses of GLP-1 receptor agonists for overweight and obesity patients [9] Company Overview - Metsera is a clinical-stage biopharmaceutical company founded in 2022, focused on developing next-generation medicines for obesity and metabolic diseases [10]